
The over-the-counter medicine scientists say may raise your dementia risk
Diphenhydramine is the active ingredient in countless over-the-counter medications. But experts say there are serious risks to taking too much of the drug—or taking it too long. Diphenhydramine, a common antihistamine found in over-the-counter allergy and sleeping medications, may increase users' risk for dementia when taken daily over a prolonged period. Experts say the drug can also be harmful if taken in large doses beyond its recommended use. Photograph by EHStock, Getty Images
If you're among the one in three adults who struggles with seasonal allergies, the one in 10 dealing with some form of insomnia, or are among the millions dealing with the occasional cold or cough, chances are you've got drugs containing diphenhydramine in your medicine cabinet. But what you may not realize is that for years doctors have been steadily warning against taking too much of the stuff.
Diphenhydramine is the active ingredient in countless over-the-counter medications. Originally approved to prevent and treat allergy symptoms, the drug has since become popular for its ability to also treat a range of other issues that include motion sickness, anxiety, cold symptoms, nausea, insomnia, and even Parkinson's disease.
Though diphenhydramine certainly has proven benefits, a preponderance of data shows there are reasons to exercise caution when taking it—especially with newer and safer alternatives available.
(Scientists knew this drug was useless—but you've been using it for decades.)
"Taking diphenhydramine is not without risk, especially as the duration of use increases," says Sayantani Sindher, a pediatrician, allergist, and immunologist at Stanford Health Care. Some of these risks include weight gain, diminished cognitive function, memory impairment, and poor sleep quality. Mounting research also suggests it is linked to higher odds of developing neurodegenerative diseases like dementia.
Despite such adverse effects, Sindher calls diphenhydramine "one of the most commonly abused medications in the United States.' She says this is, in part, because it's so prevalent in many over-the-counter formulations that treat countless everyday ailments that "consumers can unknowingly take larger doses than needed."
A spokesperson for the Consumer Healthcare Products Association—an organization that represents the over-the-counter medicine industry—told National Geographic that 'it's important to underscore that these products are not intended for long-term use.' Like all medicines, the spokesperson added, 'responsible use is essential.' What is diphenhydramine and how does it work?
Developed mid-century by American chemist George Rieveschl and first approved by the U.S. Food and Drug Administration (FDA) in 1946, diphenhydramine is what's considered a first-generation antihistamine.
Histamine is a chemical the body's immune system produces as a way of neutralizing allergens and fighting off pathogens. While some histamine is useful, too much can cause unwanted symptoms such as watery eyes, sneezing, coughing, or itchy skin. Antihistamines help prevent this by blocking the effects of histamine—though some antihistamines do so more thoroughly than others.
(Here's how different cold and flu drugs work.)
For example, newer antihistamines—known as second-generation antihistamines—usually block histamine receptors everywhere in the body except the brain and central nervous system. But first-generation antihistamines like diphenhydramine do the same while also blocking histamine receptors in the brain and central nervous system.
When diphenhydramine crosses the blood-brain barrier this way, research shows it affects the body's natural sleep-wake cycle and can trigger feelings of sleepiness. This makes the drug a popular go-to for treating insomnia. Crossing the blood-brain barrier also allows the drug to suppress the medullary region of the brain that's responsible for coordinating the cough reflex—making diphenhydramine also helpful for treating cold symptoms.
But this crossing of the blood-brain barrier also blocks another neurotransmitter, called acetylcholine. "Acetylcholine is key to memory, attention, and muscle movements," says Harita Shah, a pediatrician and clinical assistant professor of medicine at the University of Chicago Medicine. This is why diphenhydramine is also considered an anticholinergic—a class of drugs used to treat movement disorders.
Such upsides comes with downsides though as taking even recommended doses of diphenhydramine can cause "side effects like drowsiness, confusion, dry mouth, constipation, and trouble urinating," says Shah. Blurred vision and delirium can also occur, though not as frequently. (The spokesperson for the Consumer Healthcare Products Association acknowledged that the common side effects of taking diphenhydramine 'such as drowsiness or dry mouth' are 'well-established.')
Other less common side effects include "increased appetite, weight gain, dizziness, postural hypotension, and possible cardiac arrhythmia," says Gordon Sussman, a professor of medicine at the University of Toronto.
But what really worries scientists more are some of the more serious emerging risks associated with the drug.
For one, studies show that "learning is impacted in young adults taking diphenhydramine,' says Anna Wolfson, an allergist and immunologist at Massachusetts General Hospital and co-author of a 2022 research paper that urges the medical community to 'move on' from the drug.
One noted clinical trial demonstrated cognitive impairment when participants who took just a 50-milligram dose of diphenhydramine experienced lower memory retention and difficulty focusing compared to individuals not taking the drug.
(The problem with natural sleep aids.)
These diminished cognitive abilities can also worsen with age, says Sindher. She explains that the drug remains in older bodies longer than it does in children and adolescents—eventually for as long as 18 hours. "This relatively long half-life risks results in daytime sedation the following day and explains poor concentration and attention," she explains.
This is one reason, 'people who take diphenhydramine are more likely to get in car accidents or have more balance-related fractures and other injuries," says Sussman. Increased dementia risk
Longer-term use is even more worrisome as multiple studies show that diphenhydramine may also be linked to an increased risk neurodegenerative disease development.
This includes a prominent 2015 study published in JAMA Internal Medicine that found that people who took diphenhydramine daily for at least three years had a 54 percent higher risk of developing dementia than people who took the same dose for three months or less. Subsequent Europe-based research and a study from the University of British Columbia demonstrate similar findings.
(The reason dementia rates are rising is surprisingly simple.)
Although the exact mechanism behind these increased neurodegenerative risks is "still not known," says Shah, the long-term use of anticholinergic medicines like diphenhydramine 'has been shown to permanently alter the brain's structure, neurotransmission capabilities, and chemical pathways."
Even if you're only taking the drug for a short time, doctors say you should still be mindful of the risks of overconsumption. "Taking excessive amounts of diphenhydramine within 24 to 48 hours...can result in toxicity," says Corey Hannah Basch, a professor of public health at William Paterson University in New Jersey. "A toxic dose can lead to serious symptoms including seizures, confusion, rapid heart rate, hallucinations, urinary retention, and ataxia."
Indeed, in the past five years, the FDA has twice had to warn against the "serious heart problems, seizures, coma, or even death" that can accompany taking high doses of diphenhydramine and similar drugs. It did so once in 2020 and again in 2022 in response to social media trends that encouraged people to misuse the drug.
Compounding concerns is the fact that no one knows for sure how much diphenhydramine will be toxic. "An 'overdose' would be different for each person," says Wolfson. Basch agrees, noting that "there is broad medical consensus that diphenhydramine toxicity is dose dependent," and that "the severity of symptoms depends on the amount ingested."
One commonly cited study shows that worrisome but moderate symptoms of toxicity can occur when taking as little as 0.3 grams of diphenhydramine, but that its most severe symptoms, "including coma and death," Basch says, "were observed at doses of 1 gram or higher." But this higher amount may be much smaller in children, elderly adults, and people with certain medical conditions, Sussman warns.
Such concerns are why "several organizations, including the Global Allergy and Asthma European Network, support diphenhydramine being available only as a prescription" and not in its current over-the-counter form, says Jennifer Namazy, a clinical professor of medicine in the division of allergy and immunology at the Scripps Clinic healthcare system in California.
Diphenhydramine continues to be FDA approved for certain uses—including treating short-term problems such as "acute treatment of severe allergic reaction" among older populations who are at greater risk of harmful side effects, according to safety criteria from the American Geriatrics Society.
But for these people and most of the rest of us, 'the use of diphenhydramine as a first-line treatment for allergic conditions and most other situations is no longer recommended — especially with the wide availability of second-generation antihistamines as an alternative," says Aikaterini Anagnostou, a professor of pediatrics and director of the food allergy program at Texas Children's Hospital & Baylor College of Medicine.
Sindher agrees and says that second-generation antihistamines like loratadine (Claritin), cetirizine (Zyrtec), and fexofenadine (Allegra) "have limited, if any, ability to cross the blood brain barrier, which results in fewer anticholinergic side effects."
"While diphenhydramine has been trusted for decades, its impairment effects and toxicity potential make it less ideal for routine use," echoes Basch. "It's always wise to re-evaluate longstanding medications like diphenhydramine—especially when newer options offer similar relief with fewer risks."

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
American Botanical Council Acquires Full Rights to Steven Foster Photo Library
The nonprofit now owns more than 150,000 images of 1,700+ species of medicinal and aromatic plants taken by famed photographer and herbal expert Echinacea Purpurea Passiflora Incarnata Austin, Texas, June 06, 2025 (GLOBE NEWSWIRE) -- The nonprofit American Botanical Council (ABC) announces that it has obtained ownership rights to the entire collection of medicinal and aromatic plant photographs taken by the late botanist, author, and preeminent photographer Steven Foster (1957–2022).Foster was well-known and widely respected as the author or co-author of 21 books on herbs and medicinal plants. He also wrote more than 800 articles and reviews on herbal medicine, ethnobotany, sustainable sourcing, conservation, and related subjects, including more than 100 articles and reviews in ABC's peer-reviewed journal HerbalGram. His extensive photographic library includes more than 150,000 images of more than 1,700 accurately identified medicinal and aromatic plant species. This includes Foster's photos of many native American medicinal plants, as well as other plants he encountered during his travels in countries around the world, including Argentina, Armenia, Belize, China, Costa Rica, Egypt, England, Georgia, Germany, Guatemala, Japan, Montenegro, the Netherlands, Peru, Switzerland, Trinidad and Tobago, Vietnam, and elsewhere. Foster was a member of ABC's Board of Trustees for more than 20 years and president for 10 years. He provided frequent and instrumental support for HerbalGram and served as a contributing editor, peer reviewer, and author of dozens of feature-length articles. He also contributed hundreds of medicinal plant photos from his extensive library, including at least 60 photos that appeared on the magazine's cover. His photography filled nearly every issue of HerbalGram since issue 24 in 1991. After Foster's untimely death in January 2022, ABC continued to have access to and permission to use his photos in a variety of ABC publications and communications through a special arrangement with his estate. ABC continued to feature his photos on ABC's website, in publications of the ABC-AHP-NCNPR Botanical Adulterants Prevention Program (BAPP), and in HerbalGram, ABC's monthly newsletter HerbalEGram, ABC's weekly newsletter Herbal News & Events, and other ABC publications. Now, ABC has finalized the purchase of Foster's entire digital photo library, including full rights to all of the images. Credits to Foster's photographs will now read: 'Photo by Steven Foster ©2025 ABC.' 'For more than 40 years, Steven was a close personal friend and colleague and a primary contributor to ABC's nonprofit research and educational mission, publications, and programs,' said ABC Founder and Executive Director Mark Blumenthal. 'Steven's intelligence, botanical knowledge, insightful and deeply informed writing, and his compelling photography were an integral part of the development and evolution of HerbalGram and ABC. 'It has been ABC's goal not only to provide authoritative, reliable, science-based information on herbs and medicinal plants, but also to show the beauty of these plants, which we have done for decades thanks in large part to Steven's incredibly beautiful photos,' Blumenthal added. 'Now, ABC has the opportunity to continue its nonprofit educational mission with Steven's photos and to help expand the herb community and general public's awareness of and appreciation for Steven's remarkable photographic legacy. ABC Art Director Matt Magruder said: 'Securing the ownership of Steven Foster's photography library is an exciting new chapter for HerbalGram and all of ABC's various programs and publications. Steven's photography has been a foundational — and visually stunning — part of the organization from early on. As a fellow photographer, I am grateful to be able to honor Steven and to continue to share his quintessential photographic legacy through ABC's stewardship moving forward.' Michael J. Balick, PhD, member of ABC's Board of Trustees and vice president for botanical science, director and senior philecology curator of the Institute of Economic Botany at the New York Botanical Garden, said: 'I was delighted to learn that ABC has acquired the Steven Foster Photo Library. Steven's 'plant's eye view' was nothing short of extraordinary, and this is reflected in all of the artistic and scientific work that he did over so many decades. He was enthusiastic and generous about sharing his talents as a photographer and providing his guidance to anyone who asked for his advice, regardless of their level of botanical sophistication. When I invited him to illustrate the third edition of the Handbook of Poisonous and Injurious Plants [Springer, 2017], he provided his best work, and the photos that grace the pages of this reference book are not only useful for identification in cases of suspected poisoning, but also works of beautifully composed botanical art. We all miss Steven, who left us prematurely, and I am grateful to ABC and its donors for ensuring that this part of his legacy will endure, educating and captivating us all for many more decades.' Blumenthal noted that, at a time when people are beginning to use artificial intelligence as a source for botanical images, one primary benefit of Foster's photographs is the reliable and accurate identification of the depicted plant species. As an expert botanist, Foster properly identified the botanicals in his photos. Aside from the beauty of the photos, this benefit is a key feature of ABC's Steven Foster Photo Library. ABC featured a memorial tribute to Steven Foster in HerbalGram issue 133 and a pictorial of some of his medicinal plant photography in issue 134. A new pictorial of Foster's brilliant medicinal plant photos was just published in the current issue of HerbalGram, issue 143. In addition, ABC has named its newest award for botanical excellence after Foster, the ABC Steven Foster Excellence in Botanical Conservation and Sustainability Award, which is announced each spring at the annual ABC Celebration at Natural Products Expo West in Anaheim. Attachments Echinacea Purpurea Passiflora Incarnata CONTACT: Public Relations American Botanical Council 512-926-4900 ext. 129 publicrelations@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Yahoo
2 hours ago
- Yahoo
OpenAI's marketing head takes leave to undergo breast cancer treatment
OpenAI's head of marketing, Kate Rouch, has announced she's stepping away from her role for three months while she undergoes treatment for invasive breast cancer. In a post on LinkedIn, Rouch says that Gary Briggs, Meta's former CMO, will serve as interim head of marketing during her leave. "Earlier this year — just weeks into my dream job — I was diagnosed with invasive breast cancer," wrote Rouch. "For the past five months, I've been undergoing chemo at UCSF while leading our marketing team. It's been the hardest season of life — for me, my husband, and our two young kids." Rouch says her prognosis is "excellent" and that she's expected to make a full recovery. "1 in 8 American women will get invasive breast cancer," she wrote in her post. "42,000 die every year. Rates are rising for young women. I'm sharing my story [...] to get their attention and encourage them to prioritize their health over the demands of families and jobs. A routine exam saved my life. It could save yours too." Rouch, who previously worked with Briggs at Meta, joined OpenAI in December. She formerly was Coinbase's CMO, and before that led brand and product marketing for platforms including Instagram, WhatsApp, Messenger and Facebook. This article originally appeared on TechCrunch at Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Hotel carbon monoxide alarm rule reintroduced in Congress
This story was originally published on Hotel Dive. To receive daily news and insights, subscribe to our free daily Hotel Dive newsletter. U.S. Reps. Angie Craig (D-MN) and Mike Levin (D-CA) reintroduced legislation to Congress that would require carbon monoxide detectors to be installed in every hotel and short-term rental room in the country, according to an announcement Thursday. Rep. Craig previously introduced the bill, dubbed the Stay Safe Act, in 2020. In its earlier version, the Safe Stay Act was referred to the Committee on Science, Space, and Technology but did not move out of the committee. A similar law went into effect in Minnesota in August of last year, according to the announcement, though the majority of states do not require in-room carbon monoxide detectors. The American Hotel & Lodging Association has previously encouraged hotels to install carbon monoxide monitoring equipment in spaces with fuel-burning appliances and in immediately attached spaces 'at a minimum.' Craig initially introduced the Stay Safe Act in response to the hospitalization of Minnesotan Leslie Lienemann and her son, who were poisoned in a Hawthorn Suites by Wyndham in Warren, Michigan, in 2019, per The New York Times. 'My son and I suffer life-long physical and emotional effects of carbon monoxide poisoning because there was no carbon monoxide alarm in our hotel room,' Lienemann said in a statement on Craig's website. 'Carbon monoxide is undetectable without a CO alarm.' 'We have the tools to prevent carbon monoxide poisoning and save lives — and we should be using them,' Craig said in a statement. The bill specifies that compliant carbon monoxide alarms must be installed 'in each sleeping or dwelling unit within each place of public accommodation affecting commerce.' Currently, only 14 states require carbon monoxide detectors in hospitality settings, according to the John Wesley Heathco Legacy Foundation, which was founded after American travelers John Heathco and Abby Lutz died of carbon monoxide poisoning at a Hyatt resort in Mexico in 2023. AHLA's Safe Stay initiative, which offers guidelines for hotels, encourages hotels to adhere to the fire and mechanical codes in their respective jurisdictions. It also says hotel staff should be familiar with their property's carbon monoxide monitoring capabilities — including the location of detectors and sounds of alarms — and be trained in emergency procedures. 'Johnny's death should never have happened, and no family should have to endure the devastation that we have had to live with for nearly two years, and that we will live with for the rest of our lives,' said John Heathco's parents, Chuck and Jill Heathco, and his sister and brother-in-law, Keri and Tyler Bliss, in a joint statement obtained by Hotel Dive. The issue of carbon monoxide poisoning made headlines earlier this year when three American tourists died in a hotel room in Belize, per NBC News. The Stay Safe Act was again referred to the Committee on Science, Space, and Technology on Thursday. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data